Category: Labor
|
|
| |
|
California Life Science Firms to Learn "Insider" Strategies for Government Funding at 11th SoCalBio Investor & Partnership Conference
|
 |
The Center’s Flagship Investment Program provides working capital to early-stage companies
For Immediate Release: Date: February 24, 2010
Contact: Angus G. McQuilken, MLSC VP for Communications
Phone: (617) 921-7749 Email: amcquilken@masslifesciences.com
Waltham, MA – The Board of Directors of the Massachusetts Life Sciences Center today approved the launch of the 2010 Accelerator Loan Program, the second year of the Center’s flagship investment program that provides working capital to early-stage life sciences companies. The Center will begin accepting online applications on Wednesday, February 24th, 2010 with an application deadline of Wednesday, March 24, 2010. A subsequent round will be conducted in the fall, with application dates to be announced. Applications will be accepted via the Center’s web site at www.masslifescience.com.
The Program has been capitalized with $5.5 million for 2010. This year’s program will offer loans of up to $750,000 per company, an increase from the 2009 maximum loan amount of $500,000. The Program seeks to “de-risk” start-up companies that are in need of financing to serve as flexible working capital or for the purchase of capital assets to help selected companies achieve product development milestones and obtain private investment. In addition, the loan terms will now include a warrant which will give the Center the right to purchase equity in the company at a specific price within a certain time frame.
For Immediate Release: Date: 02/24/10
Contacts:
Massachusetts Life Sciences Center
Angus G. McQuilken, Vice President for Communications
Phone: 617-921-7749 Email: amcquilken@masslifesciences.com
WPI/Gateway Park
Michael Cohen
Phone: 508-868-4778 Email: mcohen@wpi.edu
Grant leverages $25 million private investment for development of a new facility that will create jobs, house young companies and provide training programs in the life sciences
Waltham, MA— The Massachusetts Life Sciences Center Board of Directors today awarded a $6.6 million grant to Worcester Polytechnic Institute (WPI) to support the next phase of life sciences related development at Gateway Park in Worcester. The grant leverages $25 million in private investment for the development of a new 80,000-square-foot life sciences facility anticipated to create 120 construction jobs and 142 new permanent jobs at completion.
The grant supports the development of WPI’s Biomanufacturing Education and Training Center (BETC); a new incubator for Massachusetts Biomedical Initiatives (MBI); and expanded academic and research space, including new facilities for the Massachusetts Academy of Math and Science. The BETC is planning a 10,000-square-foot facility that will provide hands-on biomanufacturing training to support industry workforce development. MBI is planning to expand its incubator resources by developing a new wet-lab core facility to help more companies launch, grow and provide jobs. MBI currently operates three life sciences incubators in Central Massachusetts (one of which is located in the first Gateway Park building) and has graduated 30 companies, creating 265 new jobs since 2000.
 |
|
...But what do I know?
Lessons learned from living through a couple of spin-out companies
|
|
qed@qb3 UCSF
Thursday, March 4, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
There are many lessons to be learned in the formation of spinouts. Tom will walk through his experiences going from an academic setting to a spinout company and what he has learned from this and a couple of other companies that he has been close to (Avantome, TrueMaterials, Boreal Genomics)
Tom Willis is the CEO of MLC Dx Inc. a VC backed company dedicated to the commercialization of molecular diagnostic tests. Prior to founding MLC, Tom has been an entrepreneur in the biotech industry for the past decade. After receiving his Ph.D. in physics from Stanford University, he joined the Stanford Genome Technology Center (SGTC) to work on DNA sequence analysis technologies. He held several positions at the SGTC including Associate Director in charge of technology development. While at SGTC, he co-invented the Molecular Inversion Probe technology for high throughput genotyping. In 2001, he co-founded ParAllele BioScience to develop and commercialize this technology. As its founding CEO, he led ParAllele through two rounds of VC financing a grew the company to over 80 employees. In 2005 ParAllele was acquired by Affymetrix at which time Tom served in several management positions at Affymetrix. He left in 2007 to pursue new startup opportunities. In addition to his role at MLC, Tom serves on the boards of SpinX Technologies and Boreal Genomics
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=198455
http://qb3.org/services/qed-qb3/?searchterm=qed
|
|
Risk Management and Insurance Primer for Life Science Companies
|
|
qed@qb3 - Special Event
Tuesday, February 23, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
In this discussion we will touch on the various aspects and stages of Risk Management and Insurance for Life Science Companies from start-up, through clinical trials to product commercialization. The primer will touch on all aspects of insurance from workers' compensation, property and general liability, to clinical trials, international, directors and officers and more.
Kevin Mirsky is a Principal of Saylor & Hill Co. and has been with the firm since 1991. Kevin leads Saylor & Hill Co.'s Technology and Life Science Practice in the Bay Area, providing Risk Assessment and Insurance Brokerage services to mid- and large-size clients. He has expertise in multi-national clinical trials, medical device and pharmaceutical products as well as software, hardware and web-based businesses. Kevin is active in the community, and is a member of BayBio.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=198053
For Immediate Release
February 3, 2010
Media inquiries
(Tucson, Arizona) Today, the Vail School District broke ground on the Vail Academy & High School, the district’s first K-12 school and the nation’s first K-12 school located at a university research park.
Vail High School began offering classes at the Tech Park in July 1997. Vail Academy (K-8) will join the already established Vail High School at a new site in the Tech Park. The 34,000 square foot facility is scheduled to open in July 2010.
The K-12 school will house 225 K-8 students and 225 high school students. Each grade level will accommodate approximately 25 students. The small class size provides an interactive environment where students receive personal attention. The K-12 model allows the curriculum to build on the previous grades' teaching, which provides a consistent educational foundation and the development of vast knowledge around important concepts.
|
|
Building, Compensating & Motivating
a Leadership Team
|
|
qed@qb3 - UCSF
Thursday, February 4, 2010
12:00 to 1:00 pm
Byers Hall Room 212
|
One of the most critical factors for a company's success is building an excellent team, but finding, recruiting, compensating, and ultimately motivating the best people is extremely challenging. Chris McKinley and Michael Ballenger bring decades of HR and executive recruitment experience to this subject and will share their insights and advice in this seminar.
Christine McKinley has 30 years experience working in entrepreneurial, high growth biotech and medical companies. Prior to founding Round One Resources, she was Sr.VP of Human Resources at Cell Genesys, responsible for strategic and operational HR initiatives, involving extensive staffing of a manufacturing facility, expansion of process development, manufacturing and clinical operations, merger, acquisition and restructuring activities. She began as one of the earlier employees of Genentech.
Michael Ballenger specializes in Board of Director, CEO searches as well as officer-level assignments in research, product development and all business functions. He has 23 years of experience in executive search in all segments of the life science/healthcare product industry and has focused his last 10 years on work with start-up and development stage companies. He was previously the Managing Partner of Highland Partner's San Francisco office where he built the company's first Life Science/Healthcare Products Practice and was also Sr. Director of Human Resources for Genentech.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=197756
Bread Board's NextFab Studio opened January 22, allowing students, adults, researchers and companies to fabricate and prototype novel designs in 3D. NextFab and Bread Board's Esther Klein Gallery which had an opening for the Brower Jet Propulsion Laboratory in conjunction with the open house, brought the public into the Science Center to share in the excitement and possibility that is always present.
The 3,600 square foot production space much like the gallery across the street meets a number of needs. It provides access to the materials that will generate both conceptual and physical innovation, so that the life cycle of information and commerce may perpetuate.
For Immediate Release
Contact TREO:
Laura Shaw, Sr. Vice President, Marketing and Communications
Contact Bell Independent Power Corp.:
Joseph Bell Jr., President
Contact UA Tech Park:
Jessa Turner, Media & Public Relations Coordinator
Tucson, AZ (January 19, 2010) – Bell Independent Power Corp., Rochester, New York, is a developer of Thermal Storage Technology for Concentrated Solar Power (CSP). Bell has chosen the UA Tech Park as the site of a new state of the art 5-MW solar plant with a Thermal Storage System that will be the first of its kind in the world.
The Chicago Technology Park exists as part of the larger Illinois Medical District to provide a home to the many businesses generated or attracted by the research and care provided through the District. The Research Center is the Technology Park’s business incubator where young companies and their cohort of partners may build businesses around innovation. The biotech incubator supports entrepreneurs with a network of consortia to fund and direct growth for success.
